Analysis of 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) administration in MATTERHORN: A randomized, phase 3 study of durvalumab (D) plus FLOT in resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. | Publicación